Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;12(6):7381-7388.
doi: 10.1002/cam4.5439. Epub 2022 Nov 20.

Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

Affiliations

Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

Jennifer Berrian et al. Cancer Med. 2023 Mar.

Abstract

Purpose: To determine if the COVID-19 pandemic has further exacerbated racial disparities in late-stage presentation of breast, colorectal, lung, and prostate cancers.

Methods: We conducted a registry-based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019-June 2019 (pre-COVID-19) and March 2020-June 2020 (early-COVID-19). We compared the volume of new diagnoses and stage at presentation according to race between both periods.

Results: During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre-COVID-19 period included 2120 (64.2%), and the early-COVID-19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre-COVID-19, 16.8% were diagnosed with metastatic disease, versus 20.4% early-COVID-19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non-significant proportional decline of 1.9% in Black patients diagnosed with non-metastatic breast, colorectal, lung, and prostate cancers early-COVID-19 (p = 0.71) and a non-significant proportional increase of 7% in Black patients diagnosed with metastatic disease (p = 0.71). Difference-in-difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients.

Conclusion: While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID-19 pandemic, the impact was similar for White and Black patients.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Impact of the COVID‐19 pandemic on the absolute numbers of new diagnoses of breast, colorectal, lung, and prostate cancers. Absolute numbers of new reported diagnoses of all breast, colorectal, lung, and prostate cancer pre‐COVID‐19 and early‐COVID‐19. Blue bars represent pre‐COVID‐19; red bars represent early‐COVID‐19. Figure 1 excludes cases with missing stage. This is a descriptive figure designed to highlight absolute numbers only
FIGURE 2
FIGURE 2
Impact of the COVID‐19 pandemic on stage at presentation according to disease site. Absolute numbers of new reported diagnoses of all breast, colorectal, lung, and prostate cancer pre‐COVID‐19 and early‐COVID‐19, and according to stage at disease presentation. Yellow bars represent colorectal cancers; gray bars represent lung cancer, orange bars represent prostate cancers, and blue bars represent breast cancers. Figure 2 excludes cases with missing stage. This is a descriptive figure designed to highlight absolute numbers only

Similar articles

Cited by

References

    1. Hashim D, Boffetta P, La Vecchia C, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27(5):926‐933. doi:10.1093/annonc/mdw027 - DOI - PubMed
    1. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211‐233. doi:10.3322/caac.21555 - DOI - PubMed
    1. DeLancey JO, Thun MJ, Jemal A, Ward EM. Recent trends in black‐white disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev. 2008;17(11):2908‐2912. doi:10.1158/1055-9965.Epi-08-0131 - DOI - PubMed
    1. Snyder RA, Hu CY, Zafar SN, Francescatti A, Chang GJ. Racial disparities in recurrence and overall survival in patients with locoregional colorectal cancer. J Natl Cancer Inst. 2021;113(6):770‐777. doi:10.1093/jnci/djaa182 - DOI - PMC - PubMed
    1. Kelly SP, Rosenberg PS, Anderson WF, et al. Trends in the incidence of fatal prostate cancer in the United States by race. Eur Urol. 2017;71(2):195‐201. doi:10.1016/j.eururo.2016.05.011 - DOI - PMC - PubMed